Premium
CXCR4 mutational status does not impact outcomes in patients with W aldenström macroglobulinemia treated with proteasome inhibitors
Author(s) -
Castillo Jorge J.,
Gustine Joshua N.,
Meid Kirsten,
Flynn Catherine A.,
Demos Maria G.,
Guerrera Maria L.,
Jimenez Cristina,
Kofides Amanda,
Liu Xia,
Munshi Manit,
Tsakmaklis Nicholas,
Patterson Christopher J.,
Xu Lian,
Yang Guang,
Hunter Zachary R.,
Treon Steven P.
Publication year - 2020
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25730
Subject(s) - macroglobulinemia , cxcr4 , waldenstrom macroglobulinemia , medicine , proteasome , oncology , genetics , biology , multiple myeloma , lymphoma , receptor , chemokine